Immunotherapy with interleukin-2 by constant infusion with and without adoptive cell transfer and with weekly doxorubicin.
Paciucci
P A
PA
Derald Ruttenberg Cancer Center, Mount Sinai School of Medicine, Mount Sinai Hospital, New York, NY 10029.
Holland
J F
JF
Ryder
J S
JS
Konefal
R G
RG
Bekesi
G J
GJ
Odchimar
R
R
Gordon
R
R
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003404:Creatinine / Q000097:blood; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006801:Humans; D006973:Hypertension / Q000209:etiology; D007167:Immunotherapy / Q000379:methods; D007376:Interleukin-2 / Q000008:administration & dosage*; D008214:Lymphocytes / Q000276:immunology*; D008991:Monitoring, Physiologic; D009061:Mouth Mucosa; D009369:Neoplasms / Q000628:therapy*; D012074:Remission Induction; D013280:Stomatitis / Q000209:etiology; D015430:Weight Gain
D007376:Interleukin-2; D004317:Doxorubicin; D003404:Creatinine